Explanation of antifibrotic Mcpip1 role in the liver
2019/33/N/NZ5/00916
Keywords
Descriptors
- NZ5_001: Etiologia chorób człowieka
- NZ5_003: Patogeneza chorób człowieka
- NZ3_001: Biologia komórki
Panel
NZ5 – Human and animal noninfectious diseases: etiology, mechanisms, diagnosis and treatment of diseases, poisonings and injuries (without neurological diseases)
Host institution
Uniwersytet Jagielloński, Wydział Biochemii, Biofizyki i Biotechnologii
Voivodeship: małopolskie
Principal investigator (from the host institution)
Number of co-investigators in the project: 2
Call
PRELUDIUM 17 – announced on 2019-03-15
- Amount awarded
- 139 858 PLN
- Project start date
- 2020-02-20
- Project end date
- 2023-02-19
- Project duration
- 36 months (the same as in the proposal)
- Project status
- Project settled
Project description
Download the project description in a pdf file
Note — project descriptions were prepared by the authors of the applications themselves and placed in the system in an unchanged form.
Information in the final report
Publication in academic press/journals (1)
-
MCPIP1 inhibits hepatic stellate cell activation in autocrine and paracrine manners, preventing liver fibrosis.
- Authors:
- Natalia Pydyn, Anna Ferenc, Katarzyna Trzos, Ewelina Pospiech, Mateusz Wilamowski, Olga Mucha, Piotr Major, Justyna Kadłuczka, Pedro M Rodrigues, Jesus M Banales, Jose M Herranz, Matias A Avila, Tomasz Hutsch, Piotr Malczak, Dorota Radkowiak, Andrzej Budzynski, Jolanta Jura, Jerzy Kotlinowski
- Academic press:
- Cellular and Molecular Gastroenterology and Hepatology (year: 2024, volume: -, pages: -), Publisher: Elsevier
- Status:
- Published
- DOI:
- 10.1016/j.jcmgh.2024.01.021 – link to the publication